PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Thromb Haemost 2021; 121(08): 992-1007
DOI: 10.1055/a-1535-8807
Consensus Paper

The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper

Authors

  • Grigoris T. Gerotziafas 

    1   Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France
    2   Thrombosis Center, Tenon-Saint Antoine, Hôpitaux Universitaires de l'Est Parisien, Assistance Publique Hôpitaux de Paris (APHP), France

  • Mariella Catalano

    3   Research Center on Vascular Disease & Angiology Unit, Department of Biomedical Science, L Sacco Hospital, University of Milan, Milan, Italy

  • Yiannis Theodorou

    4   Centre d'Immunologie et des Maladies Infectieuses UPMC UMRS CR7, Inserm U1135, CNRS ERL 8255, Paris, France

  • Patrick Van Dreden

    1   Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France

  • Vincent Marechal

    1   Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France

  • Alex C. Spyropoulos

    5   Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, United States
    6   Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia

  • Charles Carter

    7   Department of Clinical Research, College of Pharmacy & Health Sciences, Campbell University, Buies Creek, North Carolina, United States

  • Nusrat Jabeen

    8   Department of Microbiology, University of Karachi, Karachi, Pakistan

  • Job Harenberg

    9   Department for Physical Chemistry, Heidelberg University, Heidelberg, Germany
    10   DOASENSE GmbH, Heidelberg, Germany

  • Ismail Elalamy

    1   Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France
    2   Thrombosis Center, Tenon-Saint Antoine, Hôpitaux Universitaires de l'Est Parisien, Assistance Publique Hôpitaux de Paris (APHP), France
    6   Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia

  • Anna Falanga 

    11   Immunohematology and Transfusion Medicine Department, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy
    12   School of Medicine, University of Milan Bicocca, Monza, Italy

  • Jawed Fareed

    13   Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, Health Sciences Division, Loyola University Chicago, Maywood, Illinois, United States
    14   Department of Pharmacology and Neuroscience, Cardiovascular Research Institute, Health Sciences Division, Loyola University Chicago, Maywood, Illinois, United States

  • Petros Agathaggelou

    15   Cyprus Department of Interventional Cardiology, American Heart Institute of Cyprus, Nicosia, Cyprus

  • Darko Antic

    16   Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

  • Pier Luigi Antignani

    17   Vascular Center, Nuova Villa Claudia, Rome, Italy

  • Manuel Monreal Bosch

    18   Department of Internal Medicine, Hospital Universitario Germans Trias i Pujol de Badalona, Universidad Católica de Murcia, Murcia, Spain

  • Benjamin Brenner

    19   Thrombosis and Hemostasis Unit, Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel
    20   Bruce Rappaport Faculty of Medicine, The Technion-Israel Institute of Technology, Haifa, Israel

  • Vladimir Chekhonin

    21   Department of Fundamental and Applied Neurobiology, V. P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Ministry of Health of the Russian Federation, Moscow, Russia

  • Mary-Paula Colgan

    22   Department of Vascular Surgery, St. James's Hospital/Trinity College Dublin, Dublin, Ireland

  • Meletios-Athanasios Dimopoulos

    23   Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

  • Jim Douketis

    24   Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    25   Division of Thoracic Surgery, St. Joseph's Healthcare Hamilton, Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada

  • Essam Abo Elnazar

    26   Department of Surgery, Ministry of Health, Saudi Arabia

  • Katalin Farkas

    27   Department of Angiology, St. Imre University Teaching Hospital, Budapest, Hungary

  • Bahare Fazeli

    28   Immunology Department, Avicenna (Bu-Ali) Research Institute, Mashhad University of Medical Sciences, Iran

  • Gerry Fowkes

    29   Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom

  • Yongquan Gu

    30   Department of Vascular Surgery, Xuan Wu Hospital, Capital Medical University and Institute of Vascular Surgery, Capital Medical University, Beijing, China

  • Joseph Gligorov

    1   Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France
    31   Medical Oncology Department, CLIP(2) Galilée, Hôpital Tenon, Hôpitaux Universitaires de l'Est Parisien, Assistance Publique Hôpitaux de Paris (APHP), France

  • Mark A. Ligocki

    13   Department of Pathology and Laboratory Medicine, Cardiovascular Research Institute, Health Sciences Division, Loyola University Chicago, Maywood, Illinois, United States
    14   Department of Pharmacology and Neuroscience, Cardiovascular Research Institute, Health Sciences Division, Loyola University Chicago, Maywood, Illinois, United States

  • Tishya Indran

    32   Australia Department of Haematology, Monash Health, Clayton, Victoria, Australia

  • Meganathan Kannan

    33   Division of Blood and Vascular Biology, Department of Life Sciences, School of Life Sciences, Central University of Tamil Nadu, Thiruvarur, India

  • Bulent Kantarcioglu

    34   Department of Hematology, Okmeydani Training and Research Hospital, Istanbul, Turkey

  • Abdoul Aziz Kasse

    35   Institut du Cancer UCAD, Centre International de Cancérologie de Dakar, Dakar, Senegal

  • Kostantinos Konstantinidis

    36   5th Surgical Department, Group of Vascular Surgery, Hippokrateio General University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

  • Fabio Leivano

    14   Department of Pharmacology and Neuroscience, Cardiovascular Research Institute, Health Sciences Division, Loyola University Chicago, Maywood, Illinois, United States

  • Joseph Lewis

    37   Department of Surgery, Stony Brook Southampton Hospital, Southampton, New York, United States

  • Alexander Makatsariya

    6   Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia

  • P Massamba Mbaye

    38   Université Virtuelle du Sénégal, Dakar, Senegal

  • Isabelle Mahé

    39   Innovative Therapies in Haemostasis, Hôpital Louis Mourier, APHP, Colombes, Université de Paris, INSERM, F-75006 Paris, France

  • Irina Panovska-Stavridis

    40   University Clinic of Hematology, Skopje, Republic of North Macedonia

  • Dan-Mircea Olinic

    41   Medical Clinic No. 1, University of Medicine and Pharmacy, Cluj-Napoca, Romania

  • Chryssa Papageorgiou

    42   Service Anesthésie, Réanimation et Médecine Périopératoire, Hôpital Tenon, Hôpitaux Universitaires de l'Est Parisien, Assistance Publique Hôpitaux de Paris, Faculté de médecine, Sorbonne Université, Paris, France

  • Zsolt Pecsvarady

    43   Department of Vascular Medicine, Flor Ferenc Teaching Hospital, Kistarcsa, Hungary

  • Sergio Pillon

    44   UOSD Angiology, San Camillo-Forlanini Hospital, National Health Institute ISS, AO San Camillo Forlanini, Rome, Italy

  • Eduardo Ramacciotti

    45   Hemostasis & Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, Illinois, United States
    46   Brazilian Clinical Research Institute, São Paulo, Brazil; Science Valley Research Institute, São Paulo, Brazil

  • Hikmat Abdel-Razeq

    47   Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan

  • Michele Sabbah

    1   Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France

  • Mouna Sassi

    48   Laboratoire de Biologie, Centre de Maternité et de Néonatologie, Hôpital Fattouma Bourguiba, Monastir, Tunisia

  • Gerit Schernthaner

    49   Division of Angiology, Department of Internal Medicine 2, Medical University of Vienna, Vienna, Austria

  • Fakiha Siddiqui

    50   Cardiovascular Research Institute, Health Sciences Divisions, Loyola University Chicago, Maywood, Illinois, United States

  • Jin Shiomura

    51   Nobelpharma Co. Ltd., Chuo-ku, Tokyo, Japan

  • Anny Slama-Schwok

    1   Sorbonne Université, INSERM, UMR_S 938, Research Group Cancer, Biology and Therapeutics, Centre de recherche Saint-Antoine (CRSA), Institut Universitaire de Cancérologie, Paris, France

  • Jean Claude Wautrecht

    52   Service de Pathologie Vasculaire, Hôpital ERASME, Université Libre de Bruxelles, Brussels, Belgium

  • Alfonso Tafur

    53   Vascular Medicine, Northshore Cardiovascular Institute, Skokie, Illinois, United States

  • Ali Taher

    54   Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

  • Peter Klein-Wegel

    55   Klinik für Angiologie, Zentrum für Innere Medizin II, Ernst von Bergmann Klinikum, Potsdam, Germany

  • Zenguo Zhai

    56   Center of Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, China–Japan Friendship Hospital, Peking University Health Science Center, Capital Medical University, Beijing, China
    57   Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China

  • Tazi Mezalek Zoubida

    58   Clinical Hematology - Internal Medicine, Ibn Sina hospital, Mohammed V University, –Rabat, Morocco
    • Scientific Reviewer Committee
Weitere Informationen
  Lizenzen und Reprints
Preview

Abstract

Background One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis.

Management Non-pharmacological interventions (NPIs) are efficient mitigation strategies. The success of these NPIs is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic.

Current Issues The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and its variants. The need of a second and even third generation of vaccines has already been acknowledged by the WHO and governments.

Perspectives There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes: (1) Prevention of the SARS-CoV-2 infection, (2) Detection and early diagnosis of patients at risk of disease worsening, and (3) Anticipation of medical care (PDA).

Conclusion The “PDA strategy” integrated into state policy for the support and expansion of health systems and introduction of digital organizations (i.e., telemedicine, e-Health, artificial intelligence, and machine-learning technology) is of major importance for the preservation of citizens' health and life world-wide.

Keywords

COVID-19 - SARS-CoV-2 - pandemic - thrombosis - health care systems

* Scientific Reviewer Committee Members: Gregory Y. H. Lip, Michael Makris, Sam Schulman, Wolfgang Siess, Christian Weber




Publikationsverlauf

Eingereicht: 04. Mai 2021

Angenommen: 17. Juni 2021

Accepted Manuscript online:
24. Juni 2021

Artikel online veröffentlicht:
20. Juli 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany